A new drug designed to work on cancers with an altered BRAF gene has shown promise in an early patient trial presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.
Researchers from Tokyo Metropolitan University have discovered a new mechanism by which clumps of tau protein are created in the brain, killing brain cells and causing Alzheimer's disease. A specific mutation to an enzyme called MARK4 changed the properties of tau, usually an important part of the skeletal structure of cells, making it more likely to aggregate, and more insoluble. Getting to grips with mechanisms like this may lead to breakthrough treatments.
A team led by scientists at Scripps Research has developed a theoretical approach that could ease the process of making highly complex, compact molecules. Such molecules are often found in plants and other organisms, and many are considered desirable starting points for developing potential new drugs. But they also tend to be highly challenging for chemists to construct and modify in the lab--a process called synthesis.
Through intricate experiments designed to account for sex-specific differences, scientists at Scripps Research have collaborated to zero-in on certain changes in the brain that may be responsible for driving alcohol abuse among people with PTSD. In studies with rodents, researchers found that males and females exhibit their own distinct symptoms and brain features of PTSD and alcohol use disorder. Such differences are not typically accounted for in laboratory-based studies yet could lead to more successful clinical treatments.
Moving around in the half-light is difficult but not impossible. To help us in this undertaking we have the rods, a type of photoreceptors present in the retina of vertebrates, capable of detecting very low lights. They are the protagonists of the new study published in PNAS by a team of researchers of SISSA and CNR-Iom which reveals new and essential details of how the retina works and in particular photoreceptors.
The plant compound apigenin improved the cognitive and memory deficits usually seen in a mouse model of Down syndrome, according to a study by researchers at the National Institutes of Health and other institutions. Apigenin is found in chamomile flowers, parsley, celery, peppermint and citrus fruits. The findings raise the possibility that a treatment to lessen the cognitive deficits seen in Down syndrome could one day be offered to pregnant women whose fetuses have been diagnosed with Down syndrome through prenatal testing.
Forty co-investigators at 11 research centers will team up to leverage artificial intelligence and machine learning to bolster precision diagnostics, prognosis and the development of new treatments for Alzheimer's disease.
Can COVID-19 infection increase the risk of developing Parkinson's disease? That's the question posed by a new commentary published in the journal Trends in Neurosciences, which explores three known case studies of people developing Parkinson's-like symptoms in the weeks following infection with SARS-CoV-2, the virus that causes COVID-19. While rare, these cases provide important insights into potential long-term implications of infections.
Specific regions in cord blood DNA can help identify kids who might develop autism, according to a UC Davis MIND Institute study. The findings from the study may hold clues for early autism diagnosis and intervention.
Increasing the amount of time spent asleep immediately after a traumatic experience may ease any negative consequences, suggests a new study conducted by WSU researchers. Published today in Scientific Reports, the study helps build a case for use of sleep therapeutics following trauma exposure. The finding holds promise for populations that are routinely exposed to trauma, such as military personnel and first responders, and may also benefit victims of accidents, natural disaster, violence, and abuse.